Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart

Published on: 

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.

Related Content:

DevelopmentBusinessBusiness Videos
Novartis and Monte Rosa Therapeutics Form $2.1 Billion Global License Agreement for MGD-based Therapeutics
BioDuro-Sundia Opens New Kilogram Laboratory at Shanghai Site
Merck Acquires Modifi Biosciences